Sodium-glucose co-transporter-2 inhibitors and the risk of fractures of the upper or lower limbs in patients with type 2 diabetes: A nested case-control study

Initiation of dapagliflozin and treatment-emergent fractures

(2018) Konstantinos A. Toulis et al.   DIABETES OBESITY & METABOLISM

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany—A retrospective analysis of real-world data

(2017) S. Dombrowski et al.   OSTEOPOROSIS INTERNATIONAL

Fracture risk reduction with use of dipeptidyl peptidase-4 inhibitors: is there immortal time bias?

(2017) J. H. M. Driessen et al.   OSTEOPOROSIS INTERNATIONAL

Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial

(2016) Robert G. Josse et al.   DIABETES OBESITY & METABOLISM

Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials

(2016) H. L. Tang et al.   DIABETES OBESITY & METABOLISM

Bone Fractures with Sodium-Glucose Co-transporter-2 Inhibitors: How Real is the Risk?

(2016) Edoardo Mannucci et al.   DRUG SAFETY

Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin

(2016) John P. Bilezikian et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus

(2016) Nelson B. Watts et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis

(2016) Jason H Y Wu et al.   Lancet Diabetes & Endocrinology

Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials

(2016) Jianying Fu et al.   Scientific Reports

The Quasi-cohort Approach in Pharmacoepidemiology

(2015) Samy Suissa   EPIDEMIOLOGY

Use of dipeptidyl peptidase 4 inhibitors and fracture risk compared to use of other anti-hyperglycemic drugs

(2015) Johanna H. M. Driessen et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Characteristics and external validity of the German Health Risk Institute (HRI) Database

(2015) Frank Andersohn et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Possible adverse effects of SGLT2 inhibitors on bone

(2015) Simeon I Taylor et al.   Lancet Diabetes & Endocrinology

Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture

(2014) Johanna H.M. Driessen et al.   BONE

Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus

(2014) André J. Scheen   DRUGS

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial

(2013) Bruce Neal et al.   AMERICAN HEART JOURNAL